ScaleReady launches to improve T-cell manufacturing

By The Science Advisory Board staff writers

January 6, 2021 -- A new joint venture called ScaleReady has been launched to develop tools and technologies for use in cell and gene therapy manufacturing. The firm is a joint venture among Bio-Techne, Fresenius Kabi, and Wilson Wolf.

ScaleReady will provide sales, marketing, and application support for companies manufacturing cell and gene therapy products. Wilson Wolf's G-Rex cell culture technology, Fresenius Kabi's Lovo and upcoming Cue cell processing systems, and Bio-Techne's range of good manufacturing product (GMP) proteins, reagents, media, and gene editing technologies will be included in ScaleReady's manufacturing platform.

ScaleReady is owned equally by the three partners. Financial terms of the venture were not disclosed.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.